Press Releases

 
Press Releases
  Date Title View
Jun 12, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.0 million venture debt financing agreement with Hercules Capital, Inc. "This non-dilutive financing further extends our existing cash runway. This finan...
May 30, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking. He will be joining Baird as Managing Director in the firm's Life Sciences and Biotechno...
May 30, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 6, 2017, at 10:30 a.m. ET in New York, NY. In addition, the Company will participate on the Inflammatory Di...
May 24, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) will acquire CTP-656 and othe...
May 22, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information ("Second Request") from the United States Federal Trade Commission (FTC) in connection with the pending acquisition of CTP-656 and other assets relate...
May 17, 2017
-- FDA Requested Review of Recently Completed Non-Clinical Studies -- -- FDA Did Not Cite a Safety Concern -- LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and ...
May 2, 2017
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2017. "We expect to significantly strengthen our cash position in 2017 through ...
May 2, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in p...
Apr 25, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss fir...
Mar 6, 2017
- Vertex Pharmaceuticals to Acquire Cystic Fibrosis Candidate, CTP-656, from Concert Pharmaceuticals for up to $250 Million - - CTP-543 On Track to Advance Into Phase 2a Trial - - Conference Call Scheduled Today at 8:30 a.m. EST - LEXINGTON, Mass.--(BUSINESS W...
1
...
NextLast
= add release to Briefcase